Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$36.75 USD
-2.12 (-5.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $36.70 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Dianthus Therapeutics, Inc. has a market cap of $1.25B, which represents its share price of $38.87 multiplied by its outstanding shares number of 32.19M. As a small-cap company, DNTH's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
DNTH 36.75 -2.12(-5.45%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Other News for DNTH
DNTH forms Slingshot Bullish on September 20
DNTH makes New 52 Week High on September 18
Is DNTH gaining bullish strength? New 52 Week Closing High shows up after advancing 3.76%
Clear Street Initiates Coverage on Dianthus Therapeutics (DNTH) with a 'Buy' Rating | DNTH ...
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc